ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rituximab and safety"

  • Abstract Number: 1233 • 2018 ACR/ARHP Annual Meeting

    Rituximab Safety in Patients with Rheumatoid Arthritis. an Eleven-Year Follow-up Observational Study

    Raul Castellanos-Moreira Sr.1, Sebastian C Rodriguez-Garcia1, M. Victoria Hernández2, Virginia Ruiz-Esquide3, Oscar Camacho Sr.1, Andrea Cuervo1, Julio Ramírez3, Juan Cañete1, Jose Gomez Puerta1 and Raimon Sanmarti1, 1Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, 2Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, 3Rheumatology, Hospital Clínic de Barcelona, Barcelona, Spain

    Background/Purpose:  Rituximab (RTX) is a chimeric monoclonal antibody approved for the treatment rheumatoid arthritis (RA) patients who failed to respond to tumor necrosis factor inhibitors.…
  • Abstract Number: 2458 • 2018 ACR/ARHP Annual Meeting

    Predictors of Hypogammaglobulinemia during Rituximab Maintenance Therapy in Rheumatoid Arthritis: A 12-Year Longitudinal Multi-Center Study

    Gonçalo Boleto1, Jérôme Avouac1, Julien Wipff1, Marine Forien2, Maxime Dougados3, Christian Roux4, André Kahan1, Philippe Dieude2 and Yannick Allanore1, 1Université Paris Descartes, Sorbonne Paris Cité, Service de Rhumatologie A, Hôpital Cochin, Paris, France, Paris, France, 2Université Paris Diderot, Service de Rhumatologie, Hôpital Bichat, APHP, Paris, France, Paris, France, 3Department of Rheumatology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris Descartes University, Paris, France, Paris, France, 4Université Paris Descartes, Sorbonne Paris Cité, INSERM U1153, Service de Rhumatologie B, Hôpital Cochin, Paris, Paris, France

    Background/Purpose: Rituximab (RTX) is an anti-CD20 monoclonal antibody that selectively depletes B-cell population. Thus, it presents a potential risk for the development of hypogammaglobulinemia and…
  • Abstract Number: 2795 • 2017 ACR/ARHP Annual Meeting

    Comparison of Switching from the Originator Rituximab to the Biosimilar Rituximab GP2013 or Re‑Treatment with the Originator Rituximab in Patients with Active Rheumatoid Arthritis: Safety and Immunogenicity Results from a Multicenter, Randomized, Double-Blind Study

    Hans-Peter Tony1, Hendrik Schulze-Koops2, Klaus Krüger3, Stanley B Cohen4, Alan J. Kivitz5, Slawomir Jeka6, Edit Vereckei7, Liyi Cen8 and Dmitrij Kollins8, 1Department of Internal Medicine 2, Rheumatology and Clinical Immunology, University Hospital Würzburg, Würzburg, Germany, 2Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, 3Praxiszentrum St. Bonifatius München, München, Germany, 4Metroplex Clinical Research Centre, Dallas, TX, 5Altoona Center for Clinical Research, Duncansville, PA, 62nd University Hospital, CM UMK, Department of Rheumatology and Connective Tissue Diseases,, Bydgoszcz, Poland, 7National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, 8Clinical Development, Sandoz, a Novartis Division, Holzkirchen, Germany

    Background/Purpose: GP2013, is a biosimilar to European Union (EU) approved reference rituximab (RTX), developed in a stepwise approach that adheres to stringent biosimilar development guidelines.…
  • Abstract Number: 2796 • 2017 ACR/ARHP Annual Meeting

    A Randomized, Double Blind Trial over 52 Weeks to Demonstrate Bioequivalence of GP2013 and Reference Rituximab in Patients with Rheumatoid Arthritis

    Josef S. Smolen1, Stanley B Cohen2, Morton Scheinberg3, Tamas Shisha4, Dmitrij Kollins4, Peijuan Zhu5, Liyi Cen4, Alan J. Kivitz6, Andra Rodica Balanescu7, Juan J. Gomez-Reino8 and Hans-Peter Tony9, 1Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, 2Metroplex Clinical Research Centre, Dallas, TX, 3Rheumatology, Hospital Israelita Albert Einstein, Sao Paulo, Brazil, 4Clinical Development, Sandoz, a Novartis Division, Holzkirchen, Germany, 5Clinical Pharmacology, Sandoz, a Novartis Division, NJ, NJ, 6Altoona Center for Clinical Research, Duncansville, PA, 7Research Center of Rheumatic Diseases, “Sf. Maria” Hospital, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania, 8BIOBADASER, Santiago, Spain, Santiago de Compostela, Spain, 9Department of Internal Medicine 2, Rheumatology and Clinical Immunology, University Hospital Würzburg, Würzburg, Germany

    Background/Purpose: Rituximab (RTX) is a mAB indicated for the treatment of RA in patients with inadequate response to anti-TNF therapy. The current study compares the…
  • Abstract Number: 431 • 2016 ACR/ARHP Annual Meeting

    Wide Variations in Hepatitis B Screening Practices for Patients Receiving Rituximab

    Gabriela Schmajuk1, Chris Tonner2, Laura Trupin3, Jing Li4 and Jinoos Yazdany3, 1San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA, 2Rheumatology, University of California, San Francisco, San Francisco, CA, 3Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 4University of California, San Francisco, San Francisco, CA

    Background/Purpose: Hepatitis B reactivation in the setting of rituximab use is a potentially fatal but preventable event.  The rate of hepatitis B screening in patients…
  • Abstract Number: 2430 • 2015 ACR/ARHP Annual Meeting

    Immunological Risk Factors after Rituximab Therapy in Patients with Pediatric Rheumatic Diseases – a Prospective Single-Center Study

    Fabian Speth1, Johannes Peter Haas1 and Claas Hinze2, 1German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, 2Department of Pediatric Rheumatology and Immunology, University Hospital Münster, Münster, Germany

    Background/Purpose: Rituximab (RTX) is used in refractory pediatric rheumatic diseases (PRD). Data regarding the effects of RTX on the immune system in children and safety…
  • Abstract Number: 518 • 2014 ACR/ARHP Annual Meeting

    Risk of Infection Associated with Subsequent Biologic Use Following Rituximab—Results from a National RA Patient Registry

    Leslie R. Harrold1, George W. Reed1,2, Chitra Karki3, Robert Magner1, Ashwini Shewade4, Ani John4, Joel M. Kremer5 and Jeffrey D. Greenberg3,6, 1University of Massachusetts Medical School, Worcester, MA, 2Corrona, LLC., Southborough, MA, 3Corrona, LLC, Southborough, MA, 4Genentech, Inc, South San Francisco, CA, 5Albany Medical College and The Center for Rheumatology, Albany, NY, 6NYU School of Medicine, New York, NY

    Background/Purpose: Rituximab is a chimeric monoclonal antibody for the treatment of rheumatoid arthritis (RA). Prolonged B-cell depletion from repeated doses of rituximab may be associated…
  • Abstract Number: 469 • 2014 ACR/ARHP Annual Meeting

    Safety of Rituximab in Patients with Chronic Inflammatory Arthritis. Seven-Year Follow-up Observational Study

    Andrea Cuervo1, M. Victoria Hernández1, Sonia Cabrera1, Jose Inciarte-Mundo1, Julio Ramirez1, Virginia Ruiz-Esquide1, Juan D. Cañete2 and Raimon Sanmarti1, 1Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, 2Rheumatology, Hospital Clinic, Barcelona, Spain

    Background/Purpose: Rituximab (RTX) is a biologic therapy approved for the treatment of active rheumatoid arthritis (RA) refractory to tumour necrosis factor antagonists. It causes B…
  • Abstract Number: 2342 • 2013 ACR/ARHP Annual Meeting

    Long-Term Safety Of Rituximab: Pooled Analysis Of The Rheumatoid Arthritis Global Clinical Trial Program Over 11 Years

    Ronald van Vollenhoven1, Paul Emery2,3, Clifton O. Bingham III4, Edward Keystone5, Roy Fleischmann6, Daniel Furst7, Eva W. Hessey8, Abdul Mehbob8 and Patricia B. Lehane9, 1Karolinska Institute, Stockholm, Sweden, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 3NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 4Rheumatology, Johns Hopkins University, Baltimore, MD, 5University of Toronto, Toronto, ON, Canada, 6University of Texas Southwestern Medical Center, Dallas, TX, 7Medicine, University of California, Los Angeles, Los Angeles, CA, 8Roche Products Ltd., Welwyn Garden City, United Kingdom, 9Roche Products Ltd, Welwyn Garden City, United Kingdom

    Background/Purpose: This analysis evaluated the long-term safety of rituximab (RTX) in rheumatoid arthritis (RA) patients in a global clinical trial program. Methods: Pooled observed case…
  • Abstract Number: 2345 • 2013 ACR/ARHP Annual Meeting

    Long-Term Targeted Safety Event Rates In RA Patients Following Initiation Of Rituximab: Interim Analysis From Sunstone Registry

    Kenneth G. Saag1, Kevin L. Winthrop2, Kimberly Alexander3, Steven Francom4 and Daniel Furst5, 1Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, 2Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, 3Epidemiology, Genentech, Inc., South San Francisco, CA, 4Genentech, Inc., South San Francisco, CA, 5Rheumatology, UCLA, Los Angeles, CA

    Background/Purpose: Rituximab (RTX) is used for the treatment of rheumatoid arthritis (RA) in patients (pts) with an inadequate response to anti-TNF therapy (TNF-IR). Long-term safety…
  • Abstract Number: 1432 • 2013 ACR/ARHP Annual Meeting

    The Rate Of Serious Infections Remains Stable In Patients With Multiple Retreatments In Real life : Data From The “Auto Immunity and Rituximab” (AIR) Registry

    Jacques-Eric Gottenberg1, Philippe Ravaud2, Patrice Cacoub Sr.3, Thomas Bardin4, Alain G. Cantagrel5, Bernard Combe6, Maxime Dougados7, Rene-Marc Flipo8, Bertrand Godeau9, Loic Guillevin10, Xavier Le Loet11, Eric Hachulla12, Thierry Schaeverbeke13, Jean Sibilia14, Isabelle Pane15, Gabriel Baron16 and Xavier Mariette17, 1Strasbourg University Hospital, Strasbourg, France, 2Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, 3Department of Internal Medicine 2., CHU Pitié-Salpêtrière, Paris, France, 4Rhumatology Departement, Hôpital Lariboisière, Paris, France, 5Rheumatology, Purpan University Hospital, Toulouse Cedex 9, France, 6Rheumatology, Lapeyronie Hospital, Montpellier, France, 7Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, 8Rheumatology, Hopital R Salengro CHRU, Lille, France, 9Internal Medicine, University of Paris, AP-HP, Hôpital Mondor Créteil, Creteil, France, 10Department of Internal Medicine,, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, 11Rheumatology Department, CHU of ROUEN, Rouen, France, 12Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, 13Rhumatology departement, Groupe Hospitalier Pellegrin, Bordeaux, France, 14Rhumatologie, CHU Hautepierre, Strasbourg, France, 15Hotel Dieu University Hospital Paris, Hotel Dieu University Hospital Paris, Paris, France, 16Epidemiology & Clinical Research, Groupe Hospitalier Bichat-Claude Bernard, Paris, France, 17Rheumatology Departement, Bicêtre University Hospital, Paris, France

    Background/Purpose: Serious infections in patients with rheumatoid arthritis (RA) treated with  rituximab (RTX) are slightly more frequent in common practice than in clinical trials. Morevover,…
  • Abstract Number: 877 • 2013 ACR/ARHP Annual Meeting

    Results From The RATE-RA Study: A Multicenter, Single-Arm Study To Evaluate The Safety Of Administering Rituximab At a More Rapid Infusion Rate In Patients With Rheumatoid Arthritis

    Charles H. Pritchard1, Maria W. Greenwald2, Joel M. Kremer3, Norman B. Gaylis4, William Rigby5, Steve Zlotnick6, Carol Chung7, Birgit Jaber8 and William Reiss9, 1Rheumatology, Drexel University College of Medicine, Willow Grove, PA, 2Desert Medical Advances, Palm Desert, CA, 3Center for Rheumatology, Albany Medical College, Albany, NY, 4Arthritis & Rheumatic Disease Specialties, Aventura, FL, 5Department of Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH, 6Genentech, Inc., a Member of the Roche Group, South San Francisco, CA, 7Genentech Inc., South San Francisco, CA, 8F. Hoffmann-La Roche Ltd., Basel, Switzerland, 9Genentech, South San Francisco, CA

    Background/Purpose: The FDA-approved dose of rituximab (RTX) in rheumatoid arthritis (RA) is 2 × 1000 mg IV infusions given 2 weeks apart (1 course), with…
  • Abstract Number: 502 • 2012 ACR/ARHP Annual Meeting

    Safety and Efficacy of Rituximab in Patients with Rheumatoid Arthritis and Lung Involvement

    Elena Becerra1, Geraldine Cambridge2 and Maria J. Leandro2, 1Rheumatology, University College London, London, United Kingdom, 2Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom

    Background/Purpose: Lung involvement is common in patients with Rheumatoid Arthritis (RA), including interstitial lung disease (ILD), pleural disease and small airway disease. There are no…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology